Kyle Rawling YOU? Author Swipe

Last 10y

Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open

Ashwin Kishtagari, Brandon McMahon, Sanjay Mohan, Sheau‐Chiann Chen, Run Fan , et al. · 2025

Supplemental Tables S1-S9Supplemental Figures S1-S2

Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2024

Supplemental Tables S1-S9 Supplemental Figures S1-S2

Data from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2024

Purpose: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (PMF), or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce…

Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2024

Supplemental Tables S1-S9 Supplemental Figures S1-S2

Data from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2023

Purpose:Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce pr…

Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2023

Supplemental Tables S1-S9Supplemental Figures S1-S2

Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2023

Supplemental Tables S1-S9Supplemental Figures S1-S2

Data from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2023

Purpose:Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce pr…

Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2023

Supplemental Tables S1-S9 Supplemental Figures S1-S2

Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2023

Supplemental Tables S1-S9 Supplemental Figures S1-S2

Data from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open

Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay Mohan , et al. · 2023

Purpose:Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce pr…

Fetching topic information...